MedTrace Logo

Communication Regarding Preclinical Dementia Diagnostic and Diagnostic Disclosure Among Patients with MCI and SCD

NCT06621758 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2024-10-01

No results posted yet for this study

Summary

The study investigate what information individuals with SCD or MCI and their co-participant would like to receive during pre-diagnostic counseling and diagnostic disclosure, and how this information should be conveyed.

Conditions

  • Alzheimer Disease
  • Mild Cognitive Impairment (MCI)
  • Subjective Cognitive Decline (SCD)

Interventions

OTHER

questionnaire

Questionnaire regarding biomarker counseling and diagnostic disclosure

Sponsors & Collaborators

  • Toulouse University Hospital, Department of Geriatric & Internal Medicine, France

    collaborator UNKNOWN

  • Universitair Ziekenhuis Brussel, Department of Neurology, Belgium

    collaborator UNKNOWN

  • University Medical Centre Ljubljana, Department of Neurology, Slovenia

    collaborator UNKNOWN

  • Danish Dementia Research Centre

    lead NETWORK

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-15
Primary Completion
2026-02-01
Completion
2026-08-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06621758 on ClinicalTrials.gov